ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has a beta value of 2.04 and has seen 1,614,457 shares traded in the last trading session. The company, currently valued at $710.18 Million, closed the last trade at $3.3 per share which meant it lost -$0.16 on the day or -4.62% during that session. The ZIOP stock price is -80.3% off its 52-week high price of $5.95 and 37.58% above the 52-week low of $2.06. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.56 Million shares traded. The 3-month trading volume is 2.96 Million shares.
The consensus among analysts is that ZIOPHARM Oncology Inc. (ZIOP) is an Overweight stock at the moment, with a recommendation rating of 2.6. 1 analysts rate the stock as a Sell, while 1 rate it as Overweight. 3 out of 8 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.1.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) trade information
Despite being -4.62% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the ZIOP stock price touched $3.66-9 or saw a rise of 9.84%. Year-to-date, ZIOPHARM Oncology Inc. shares have moved 30.95%, while the 5-day performance has seen it change -6.78%. Over the past 30 days, the shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have changed -9.09%. Short interest in the company has seen 39.02 Million shares shorted with days to cover at 13.18.
Wall Street analysts have a consensus price target for the stock at $5.67, which means that the shares’ value could jump 71.82% from current levels. The projected low price target is $3 while the price target rests at a high of $7.5. In that case, then, we find that the current price level is +127.27% off the targeted high while a plunge would see the stock lose -9.09% from current levels.
ZIOPHARM Oncology Inc. (ZIOP) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +16.8% over the past 5 years. Earnings growth for 2021 is a modest +45.6%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s Major holders
Insiders own 9.6% of the company shares, while shares held by institutions stand at 57.16% with a share float percentage of 63.23%. Investors are also buoyed by the number of investors in a company, with ZIOPHARM Oncology Inc. having a total of 224 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 18.56 Million shares worth more than $46.77 Million. As of December 30, 2020, Blackrock Inc. held 8.62% of shares outstanding.
The other major institutional holder is Vanguard Group Inc. (The), with the holding of over 15.97 Million shares as of December 30, 2020. The firm’s total holdings are worth over $40.24 Million and represent 7.42% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also the top two Mutual Funds that are holding company’s shares are Trust for Advised Port-Miller Opportunity Trust and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of March 30, 2021, the former fund manager holds about 4.27% shares in the company for having 9200000 shares of worth $33.12 Million while later fund manager owns 7.95 Million shares of worth $28.62 Million as of March 30, 2021, which makes it owner of about 3.69% of company’s outstanding stock.